Testing an injection for advanced dry AMD with geographic atrophy
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests whether a monthly injection of pozelimab into the eye can slow the growth of geographic atrophy (a late form of dry age-related macular degeneration). It may help people who have significant vision loss from this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have geographic atrophy (a specific type of damage) in at least one eye because of dry AMD.
- The damaged area in your study eye must be at least the size of a dime (2.5 mm²).
- Your vision in the study eye must be worse than 20/63 on an eye chart.
- You cannot have had any other eye injections (except for geographic atrophy treatment at least 3 months ago).
- You cannot have other serious eye diseases like high eye pressure, diabetic retinopathy, or eye infections.
- You cannot have already taken any systemic medications for dry AMD (vitamins or supplements are okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
This trial is testing a new eye implant (TO-O-1007) to see if it's safe and helps slow vision loss from geographic atrophy, a late stage of dry age-related macular degeneration (AMD). The implant is placed inside the eye and releases medicine over time.
This trial tests a daily eye drop (GAL-101) to see if it can slow the growth of geographic atrophy lesions in people with dry age-related macular degeneration (AMD) when the center of the macula is not yet involved.
Hear when a new Geographic Atrophy (GA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.